INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

NCT04580485 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Bladder Cancer
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Castration Resistant Prostate Cancer
Colorectal Cancer
Gastric/ Gastroesophageal Junction
Hepatocellular Carcinoma
Pancreatic Ductal Adenocarcinoma
Squamous Carcinoma of the Anal Canal

Interventions

DRUG: INCB106385
DRUG: INCMGA00012

Sponsor

Incyte Corporation